OpenURL Connection Search

Select item for more details and to access through your institution.

Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder.
Published in:
Drug Metabolism & Personalized Therapy, 2018, v. 33, n. 4, p. 187, doi. 10.1515/dmpt-2018-0019
By:
- Zastrozhin, Michael S.;
- Antonenko, Anastasiya P.;
- Nesterenko, Elena V.;
- Seyfullaeva, Leyla I.;
- Mustafina, Violetta R.;
- Esakova, Antonina P.;
- Grishina, Elena A.;
- Sorokin, Alexandr S.;
- Skryabin, Valentin Yu.;
- Savchenko, Ludmila M.;
- Bryun, Evgeny A.;
- Sychev, Dmitry A.
Publication type:
Article
Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
Published in:
Drug Metabolism & Personalized Therapy, 2017, v. 32, n. 3, p. 129, doi. 10.1515/dmpt-2017-0021
By:
- Sychev, Dmitry A.;
- Zastrozhin, Mikhail S.;
- Miroshnichenko, Igor I.;
- Baymeeva, Natalia V.;
- Smirnov, Valery V.;
- Grishina, Elena A.;
- Ryzhikova, Kristina A.;
- Mirzaev, Karin B.;
- Markov, Dmitry D.;
- Skryabin, Valentin Y.;
- Snalina, Nataliya E.;
- Nosikova, Polina G.;
- Savchenko, Ludmila M.;
- Bryun, Evgeny A.
Publication type:
Article
Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.
Published in:
Human Psychopharmacology: Clinical & Experimental, 2018, v. 33, n. 6, p. N.PAG, doi. 10.1002/hup.2677
By:
- Zastrozhin, Michael S.;
- Sorokin, Aleksandr S.;
- Agibalova, Tatyana V.;
- Grishina, Elena A.;
- Antonenko, Anastasiya Р.;
- Rozochkin, Ilya N.;
- Duzhev, Denis V.;
- Skryabin, Valentine Y.;
- Galaktionova, Tatyana E.;
- Barna, Ilya V.;
- Orlova, Anna V.;
- Aguzarov, Albert D.;
- Savchenko, Ludmila M.;
- Bryun, Evgeny A.;
- Sychev, Dmitry A.
Publication type:
Article

Found: 3

Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder.

Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.

Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.